MUTHIA APRILIANI KHOIRUNNISA, - (2025) ANALISIS UTILITAS BIAYA PADA PASIEN PNEUMONIA DI RS PARU DR. H. A. ROTINSULU MENGGUNAKAN INSTRUMEN EQ-5D-5L. Skripsi thesis, Sekolah Tinggi Farmasi Indonesia.
![[img]](http://repository.stfi.ac.id/style/images/fileicons/text.png) |
Text
S_PSSF_A242047_Title.pdf Download (615kB) |
|
Text
S_PSSF_A242047_Chapter1.pdf Restricted to Repository staff only Download (266kB) |
|
Text
S_PSSF_A242047_Chapter2.pdf Restricted to Repository staff only Download (317kB) |
|
Text
S_PSSF_A242047_Chapter3.pdf Restricted to Repository staff only Download (261kB) |
|
Text
S_PSSF_A242047_Chapter4.pdf Restricted to Repository staff only Download (383kB) |
|
Text
S_PSSF_A242047_Chapter5.pdf Restricted to Repository staff only Download (254kB) |
|
Text
S_PSSF_A242047_Appendix.pdf Restricted to Repository staff only Download (1MB) |
Abstract
Pneumonia merupakan penyakit infeksi saluran pernapasan bawah dengan angka morbiditas dan mortalitas tinggi di Indonesia serta menimbulkan beban ekonomi signifikan. Evaluasi efisiensi pengobatan diperlukan untuk mendukung kebijakan pembiayaan rumah sakit yang berkelanjutan. Penelitian ini menganalisis cost-utility pengobatan pasien pneumonia di RS Paru Dr. H. A. Rotinsulu menggunakan instrumen EQ-5D-5L tanpa konversi ke QALY. Desain penelitian observasional analitik cross-sectional dilakukan pada 80 pasien dewasa dan lansia selama Agustus-September 2025. Data utilitas diperoleh melalui kuesioner EQ-5D-5L, sedangkan data biaya dari rekam medis. Analisis menggunakan uji Mann-Whitney untuk perbandingan nilai utilitas antar kelompok dan Rasio Unit Biaya (RUB) untuk menilai efisiensi antar regimen antibiotik azitromisin + seftriakson dan levofloksasin. Rata-rata utilitas pasien dengan azitromisin + seftriakson sebesar 0,637 ± 0,2396, sedangkan levofloksasin 0,699 ± 0,2492 (p = 0,297). Total biaya terapi kombinasi lebih tinggi (Rp. 17.172.732,85) dibanding levofloksasin (Rp. 7.610.296,07). RUB menunjukkan levofloksasin lebih efisien secara ekonomi (Rp. 10.887.404,96/unit utilitas) dibanding kombinasi (Rp. 26.958.764,29/unit utilitas). Variat usia, jenis kelamin, dan pekerjaan tidak berpengaruh terhadap nilai utilitas, sedangkan variat pendidikan berpengaruh signifikan (p = 0,047). Levofloksasin disimpulkan sebagai terapi pneumonia yang lebih efisien dengan biaya lebih rendah dan kualitas hidup pasien lebih baik. ----- Pneumonia is a lower respiratory tract infection with high morbidity and mortality rates in Indonesia and poses a significant economic burden. Evaluating treatment efficiency is essential to support sustainable hospital financing policies. This study analyzed the cost-utility of pneumonia treatment at RS Paru Dr. H. A. Rotinsulu using the EQ-5D-5L instrument without conversion to QALY. An analytical observational cross-sectional design was conducted on 80 adult and elderly patients during August–September 2025. Utility data were obtained through the EQ-5D-5L questionnaire, while cost data were collected from medical records. The Mann-Whitney test was used to compare utility values between groups, and the Cost per Utility Ratio (RUB) was calculated to assess the economic efficiency of two antibiotic regimens: azithromycin + ceftriaxone and levofloxacin. The mean utility scores were 0.637 ± 0.2396 for azithromycin + ceftriaxone and 0.699 ± 0.2492 for levofloxacin (p = 0.297). The total treatment cost was higher for the combination regimen (Rp. 17,172,732.85) than for levofloxacin (Rp. 7,610,296.07). The RUB indicated that levofloxacin was more cost-efficient (Rp. 10,887,404.96/utility unit) than the combination regimen (Rp. 26,958,764.29/utility unit). Age, sex, and occupation did not significantly affect utility values, while education level had a significant effect (p = 0.047). Levofloxacin is concluded to be a more efficient pneumonia therapy with lower cost and slightly better patient quality of life.
| Item Type: | Thesis (Skripsi) |
|---|---|
| Uncontrolled Keywords: | Analisis Utilitas Biaya, Azitromisin-Seftriakson, EQ-5D-5L, Levofloksasin, Pneumonia. ------- Azithromycin-Ceftriaxone, Cost-Utility Analysis, EQ-5D-5L, Levofloxacin, Pneumonia |
| Subjects: | R Medicine > R Medicine (General) R Medicine > RA Public aspects of medicine |
| Divisions: | Program Studi S1 Farmasi |
| Depositing User: | pustakawan - - |
| Date Deposited: | 20 Nov 2025 05:28 |
| Last Modified: | 20 Nov 2025 05:28 |
| URI: | http://repository.stfi.ac.id/id/eprint/3536 |
Actions (login required)
 |
View Item |
